Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus partners with Guardant Health and Apollo Hospitals to introduce Shield MCD in India
Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory.
Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test
Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and improve patient outcomes across the nation, making advanced screening more accessible.
Zydus Lifesciences, Apollo Hospitals partner to expand access to multi-cancer blood test in India
Zydus Lifesciences and Apollo Hospitals partner to expand access to Shield Multi-Cancer Detection blood test in India, screening 10 common cancers.
Zydus Lifesciences extends Sterling Biotech API business acquisition deadline to Sept 30
Shares of Zydus Lifesciences Ltd ended at ₹1,121.45, up by ₹1.81, or 19.95%, on the BSE.
Zydus Lifesciences enters into JV with Sunshine Healthcare
To establish pharma manufacturing facility in Sri Lanka
Zydus, Sunshine to set up $20 million pharma JV in Sri Lanka
Indian pharmaceutical giant Zydus Lifesciences has partnered with Sri Lanka's Sunshine Healthcare Lanka to establish a new manufacturing facility. This $20 million joint venture, Zydus Sunshine Lifesciences, will be located in the Horana Export Processing Zone. The project aims to boost local drug production, decrease reliance on imports, and improve medicine accessibility.
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
Buy, Sell Or Hold: L&T, Vedanta, Varun Beverages, Coforge And Zydus Lifesciences — Ask Profit
Market experts shared buy, sell and hold recommendations for an array of stocks.
GIC shares dip 4% as Rs 3,088 crore OFS opens for retail investors. Should you participate?
General Insurance Corporation of India shares dropped 4% as the government's OFS opens for retail investors today at a discount. Meanwhile, Zydus Lifesciences successfully completed its cash tender offer for Assertio Holdings Inc., making it a wholly-owned subsidiary. This acquisition aims to boost Zydus's pipeline of innovative drugs.
Zydus Lifesciences completes acquisition of Assertio
The company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding shares of common stock of Assertio Holdings Inc, Zydus Lifesciences said in a regulatory filing.
Zydus Lifesciences among 4 stocks that hit 52-week highs & rallied up to 17% in a month
The Sensex ended marginally higher, while four BSE 200 stocks touched fresh 52-week highs, signaling strong investor confidence. Zydus Lifesciences, Apollo Hospitals, Federal Bank and Adani Ports reached their highest levels in a year, supported by steady recent gains.
Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?
Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and Software. These offers, collectively valued at approximately Rs 1,185 crore, are closing on Wednesday. Eligible shareholders can participate in these corporate actions, which represent a chance to sell shares at a premium.